Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.46 |
| ▸ | GCG | P01275 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12647411 | 0.88 | HDAC3 (0.49) | GCGRSMN1; SMN2PPARDTRPV1EPHX2 | |
| SCHEMBL13876391 | 0.85 | NPC1 (0.54) | GCGRNPC1RAB9ASMN1; SMN2GRM5 | |
| SCHEMBL13876367 | 0.85 | LIPE (0.51) | GRM5PPARDTRPV1SCDEPHX2 | |
| SCHEMBL13876401 | 0.84 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2GRM5EPHX2 | |
| SCHEMBL13876398 | 0.82 | SMN1; SMN2 (0.54) | NPC1RAB9ASMN1; SMN2GRM5GCG | |
| SCHEMBL13876984 | 0.81 | TRPV1 (0.55) | GCGRNPC1RAB9ASMN1; SMN2TRPV1 | |
| SCHEMBL12966949 | 0.79 | MCHR1 (0.56) | NPC1RAB9ASMN1; SMN2TRPV1EPHX2 | |
| SCHEMBL5128240 | 0.79 | RXFP1 (0.56) | NPC1SMN1; SMN2TRPV1 | |
| SCHEMBL13876811 | 0.78 | RAB9A (0.50) | NPC1RAB9ASMN1; SMN2GRM5GCG | |
| SCHEMBL13876371 | 0.77 | LIPE (0.54) | RAB9AGRM5SCDEPHX2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| WO-2007098352-A2 | SUBSTITUTED PYRIDINEAMIDE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | GCGR 3532/4885NPC1 1396/4885RAB9A 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.